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Abstract
Human Papillomavirus vaccines are widely hailed as a sweeping pharmaceutical innovation for the universal
benefit of all women. The implementation of the vaccines, however, is far from universal or equitable. Socio-
economically marginalized women in emerging and developing, and many advanced economies alike, suffer a
disproportionately large burden of cervical cancer. Despite the marketing of Human Papillomavirus vaccines as the
solution to cervical cancer, the market authorization (licensing) of the vaccines has not translated into universal
equitable access. Vaccine implementation for vulnerable girls and women faces multiple barriers that include high
vaccine costs, inadequate delivery infrastructure, and lack of community engagement to generate awareness about
cervical cancer and early screening tools. For Human Papillomavirus vaccines to work as a public health solution,
the quality-assured delivery of cheaper vaccines must be integrated with strengthened capacity for community-
based health education and screening.
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Introduction
In 2006, Gardasil
® or Silgard
® (Merck), an adjuvanted
vaccine against four Human Papillomavirus (HPV) types,
was licensed for market in the Gabon, followed by the
US, Canada and more than 100 other countries [1].(See
additional file 1: appendix) Initial recommendations
for use of Gardasil
® in Canada and the US included pre-
coitarchal 9-13 year-old females and 14-26 year-old
females even if already sexually active, with a history of
cervical abnormalities or prior HPV exposure [2,3]. The
vaccine was not recommended for females who were
pregnant or less than 9 years of age. For women older
than 26 years, immunization could be considered accord-
ing to individual circumstances. In May 2007, another
HPV vaccine, Cervarix
™ (GlaxoSmithKline) became
available in Australia for females aged 10 to 45, in
September 2007 in the European Union (EU) and in the
US in 2009 for females aged 10 to 25 [4-6]. In 2009, the
U.S. Food and Drugs Administration (FDA) licensed
the use of Gardasil
® for 9-26 year-old males against geni-
tal warts caused by HPV 6 and 11 [7].
Gardasil
® and Cervarix
™ are prophylactic vaccines for
the primary prevention of HPV types 16 and 18 (impli-
cated in 70 per cent of cervical cancers). Additionally,
Gardasil
® protects against HPV types 6 and 11 (implicated
in genital warts, which are non-lethal but painful and hard
to treat) [8-10]. A 3-dose intramuscular administration
(currently costing approximately US$ 360) at 0, 1-2 and 6
months is required [6]. The vaccines generate a relatively
robust immune response against targeted HPV types in
15-25 year old females who are pre-coitarchal and/or
DNA and serologically negative for the targeted HPV
types [11,12]. For both vaccines, the immune response in
older women (25-45 years) is stronger than natural infec-
tion levels but less than that in 9-15 year olds [13,14].
HPV vaccines have been formally recommended,
although not uniformly adopted, for large-scale use in the
public sector healthcare systems and national immuniza-
tion programmes of the wealthier countries of Europe,
North America and Australasia [1,15,16]. In developing
countries, however, HPV vaccines are not available
through national immunization programs. (Following the
usage of the International Monetary Fund, and in the
absence of other established naming conventions, we
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developing economies [17].) Cost is a leading barrier to
equitable delivery of HPV immunization in developing
countries, where limited health budgets must address mul-
tiple contending priorities [18]. The high vaccine cost can
be linked to the monopoly pricing power of vaccine manu-
facturers seeking to recover high development costs. Their
retention of exclusive patent rights and their power to
keep vaccine prices high are aided by the absence of com-
pulsory licenses, which could authorize the competitive
development of cheaper biogenerics through developing
country manufacturers [19-21]. Public sector funding, the
aid of vaccine funding consortia such as the Global Alli-
ance for Vaccines Initiative (GAVI), and suitable technol-
ogy transfer mechanisms are crucial to make HPV
vaccines available at affordable prices in developing coun-
tries [19-21].
Analytical approach
Taking a science studies approach, we regard vaccines as
socio-technical objects that have technical, cultural, his-
torical, economic, geo-political, and ethical dimensions
[22]. While vaccination is a technical means to achieving
immune protection against disease, immunization
encompasses technical means and socio-political settings,
actors, plans, objectives and results. Thus, through this
paper, we adopt the term ‘immunization’ in preference to
‘vaccination.’
Furthermore, we draw on the Erickson-DeWals-Farand
analytical framework to examine the implementation of
HPV vaccines [23]. That framework suggests that the
inclusion of a vaccine in a publicly funded immunization
program requires consideration of both technical and
social factors, and of their interrelationship. These factors
include disease burden, vaccine efficacy, safety, and
immunogenicity, absolute cost and marginal cost-effec-
tiveness ratios, immunization strategy, implementation
feasibility, delivery resources, and dose schedules, and
equally important, public knowledge and acceptance, and
the political implications of immunization strategy, such
as mandatory or elective immunization [23]. HPV immu-
nization exemplifies vaccine politics. It not only activates
debate on gender, freedom, safety, responsibility and
management of adolescent sexuality, but also raises ques-
tions surrounding equity in delivering new vaccines to
the world’s poorest regions.
While the Erickson-DeWals-Farand framework was
developed for the Canadian context, we extend its scope
to examine the challenges for HPV vaccine implementa-
tion, particularly in developing countries. Vaccines are
transnational commodities, subject to national and inter-
national regulatory decision-making related to standards
of safety, efficacy and quality. As with all health technolo-
gies, however, vaccines are not created or distributed
equally. Diseases endemic in developing countries remain
under-researched. Even when effective preventions and
therapies are discovered, they are often unavailable to
people in developing economies, including those in high-
income countries. HPV immunization is a case in point.
Currently, developing countries bear about 80 per cent of
the global mortality from cervical cancer, i.e., an esti-
mated 242,000 compared to 33,000 deaths in high-
income countries [24-26]. Given the gaps in secondary
prevention, HPV immunization would seem the obvious
intervention to control mortality from cervical cancer in
developing countries. Unfortunately, the implementation
of HPV vaccines in resource-poor regions faces not only
the barriers of vaccine cost, competing health priorities,
and public acceptance, but also the systemic lack of infra-
structure that inhibits secondary prevention through cer-
vical screening. Further, lack of awareness and social
restrictions on gynecological examination prevent
women from accessing screening services when available.
The challenges of secondary prevention
In this section, we elaborate on the infrastructure and
social barriers to secondary prevention of HPV-related
disease. These gaps are persistent and will continue to
hamper immunization strategies, even when HPV vac-
cines are made readily available in developing countries.
Of the over-100 classified genotypes of HPV, over 40
types can infect the upper respiratory-digestive tracts
and anogenital areas. In most cases, HPV infection is
cleared or becomes undetectable, causing no disease;
however, persistent HPV infection is causally related to
the development of cancers and genital warts. Over 99%
of cancers of the uterine cervix are attributed to persis-
tent infection by HPV 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66 and 68, in that order of frequency. HPV is
also associated with external genital warts, respiratory
papillomatosis, and head, neck, anal, penile, vulvar and
vaginal cancers [27-31].
Cervical cancer is generally marked by a long latency
period, during which lesions progress through identifi-
able stages to invasive growth. Secondary prevention
involves screening of asymptomatic women for detec-
tion, triage, management and monitoring of precancer-
ous abnormal cells and atypical squamous cells of
undisclosed significance (ASCUS). Screening methods
include conventional cytology (Papanicolaou or ‘Pap’
smears, microscope examination of slide-mounted cervi-
cal cell samples), Liquid-Based Cytology (LBC), Visual
Inspection with Acetic Acid (VIA), Visual Inspection
with Lugol’s Iodine (VILI), and more recently HPV
DNA tests for triage of women with ambiguous cytology
to colposcopy or for surveillance of women older than
30 years for the presence of high-risk HPV DNA
[32,33].
Graham and Mishra International Journal for Equity in Health 2011, 10:27
http://www.equityhealthj.com/content/10/1/27
Page 2 of 11Although there is still no treatment for HPV, since the
1950s, cytologic screening has been a key tool in preven-
tion of cervical cancer. In high-income economies, orga-
nized programs for screening and post-screening
treatment have reduced morbidity and mortality from
cervical cancer through standardised systems of screen-
ing, monitoring, and recall-and-reminder [24-26,32-34].
Resource-poor settings in developing countries, however,
often lack primary physicians, screening equipment (e.g.,
colposcopes), trained laboratory personnel (e.g., cytotech-
nicians), and necessary expertise and capacity for screen-
ing quality assurance [34]. The lack of effective screening
programs is often combined with inadequate knowledge
about cervical cancer (causes, symptoms, progression and
treatment), even among healthcare workers [35]. In
emerging economies (e.g. Malaysia) and high-income
Asian economic regions (e.g. Hong Kong), cervical
screening can still be hampered by embarrassment sur-
rounding sexually transmitted infections (STI) and gyne-
cological examination, as well as inadequate awareness
about HPV-related risks and protections [36,37].
Even in high-income countries, availability of screen-
ing services does not always translate into accessibility
for socioeconomically marginalized and vulnerable girls
and women. In Canada, the US, the UK, and Australia
cervical cancer is higher among indigenous and minority
women, who experience the health effects of poverty,
inadequate insurance, linguistic barriers, insufficient
knowledge of health needs and risks, lack of trust in
health services, and shame regarding gynecological con-
sultations (conversation) and examination [38-45].
The labor-intensive assessment of Pap smears is asso-
ciated with false negatives and low sensitivity, which
require women to repeat the test. The American Congress
of Obstetricians and Gynecologists (ACOG) recommend
that screening start at age 21, to be repeated once every 2
years until age 30 and then every 3 years until 65-70 [46].
Despite repeated efforts to standardize cytologic reporting
guidelines and screening practice, there are knowledge
gaps and disagreements over the management of patients,
in particular those with ASCUS and low-grade lesions,
care for women older than 65 years, and the effects of
HPV immunization on screening initiation and intervals
[47-51].
Screening repeats demand follow-up compliance,
which is a particular challenge in remote impoverished
rural areas, where women must schedule time away
from necessary daily tasks (such as herding, fetching
water or firewood) or travel long distances to clinics to
be tested. Ensuring compliance requires maintaining
screening registries and establishing mechanisms for
reminders and follow-ups that do not provoke anxiety
or cause embarrassment among women [52]. Inadequate
networks, personnel and expertise inhibit public
education, disease surveillance and follow-up monitoring
in resource-poor settings.
The implementation of the other screening methods
also faces challenges. Although HPV testing is less
affected by subjectivity or artifact than cytology, it
requires more laboratory facilities, costs more than Pap
tests, and can be difficult to accomplish in developing
countries. Further, HPV testing has higher sensitivity
but lower specificity than cytology, implying fewer false
negatives but increased false positives and over-triaging
to colposcopy. This can increase resource demands on
healthcare and anxieties and physical burdens for
patients. Although new and cheaper HPV tests are
being developed, they are not yet available for wide-
spread use in developing countries [53-55]. Although
LBC allows a combination of cytology and HPV testing,
cytology itself remains error-prone. Inexpensive visual
screening procedures such as VIA and VILI are easier
to implement in developing settings and local health
workers can be trained to do them. The procedures,
however, lack guidelines and the readings are highly
subjective, error-prone and not easily reproducible [56].
Women in remote rural areas are at greater risk of cervi-
cal malignancies because they have limited access to cervi-
cal screening and appropriate treatment. Further, they
frequently present for the first examination with late stage
malignancies and co-morbidities such as malnourishment,
anemia, malaria and HIV/AIDS [57-59]. In developing
countries, the resource limitations of medical services,
including oncology, constrain ‘structure’ (the capacity of
the medical system to manage disease). Structural limita-
tions constrain ‘access’ (availability, spatial accessibility,
affordability, accommodation, acceptability, and aware-
ness) and negatively impact ‘process’ (the quality of care
from entry to discharge, and post-discharge) and ‘out-
comes’ (the effects of medical intervention on survival,
quality of life, patient awareness and behavior) [60].
Late presentation and the lack of therapeutic options (e.
g., cryotherapy or loop electrosurgical excision for cervical
intraepithelial neoplastic lesions; cold knife conization and
simple to radical hysterectomy for micro-invasive cancers;
irradiation and/or chemotherapy for more advanced
stages) probably explain the observed 5-year survival rates
of less than 25% in Uganda and Zimbabwe. This is in con-
trast to 60-75% survival rates in high-income countries.
Women may be ashamed of or resigned to their condition.
They may not obtain or complete available treatment
because of stigma associated with hysterectomy or the fear
of hair loss, for example, from chemotherapy [60,61].
Vaccine rhetoric: Unpacking the claims
Although HPV immunization has the potential to
address the challenges of screening, a number of social
and policy barriers still prevent its implementation as a
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awareness, for example, would facilitate both primary
and secondary prevention by tackling issues such as
embarrassment surrounding STIs and the public recep-
tion of HPV immunization. Vaccines are most often
given to healthy, young (immunologically naïve) indivi-
duals. The administration of a vaccine is invasive, can
be painful, and has the potential of adverse events;
harms and benefits must be weighed. Efforts to commu-
nicate and exchange information could promote accep-
tance and uptake. Commercial rhetoric, however, has
taken precedence over public health education about
HPV, its related diseases, and the prophylactic effects
and limitations of HPV vaccines.
Rhetoric has played a major role in industry marketing
and how the entire range of stakeholders, including
industry, scientists, health care providers and the public,
view the vaccine and HPV implementation. The HPV
vaccine has become a contested object where industry
advertising and profit motives have pre-empted its pub-
lic health value.
Mandatory HPV immunization has been criticised as a
violation of parental autonomy for the prevention of a
non-casually transmitted infection, a misuse of taxpayers’
money for a vaccine of unknown effectiveness at the
expense of more pressing public health issues, an unneces-
sary addition to overloaded vaccine schedules, a promo-
tion of teenage promiscuity, and a devaluation of
abstinence messages. Mandatory immunization supporters
argue that abstinence is ineffective in protecting against
STI, that secondary prevention of cervical cancer has irre-
mediable gaps, that there are already mandates for Hepati-
tis B Virus (HBV) immunization, and socio-economically
vulnerable women must be protected against cervical
cancer [62-64].
HPV vaccines are marketed as a women’s right, choice
and duty for health security, exemplified in the Gardasil ‘I
choose’ commercials [65,66]. Socioeconomic realities pose
barriers to access and choice, however, for immunization
and screening [67]. Additionally, HPV and cervical cancer
affect the families and social and economic networks of
women who succumb to the disease because they lack
access to both prevention and treatment. The advertising
around HPV vaccines conflates HPV infection, which is
widely prevalent and easily transmitted, with cervical
cancer, which is “ar e l a t i v e l yrare consequence of a common
infection“ [68: 365]. On occasion, the scientific literature
tends to equate HPV immunization with the ‘end of cervi-
cal cancer’ [69,70].
Pharmaceutical advertising of the so-called ‘cervical can-
cer vaccine’ resonates with an operative dilemma for pub-
lic health ‘social marketing’: Is the acceptability of the
vaccine improved by presenting it as ‘anti-cancer’, instead
of ‘anti-STI’ [71]? On the one hand, Gardasil receives high
acceptance from parents who wish to protect the health of
their children. On the other hand, parents worry that their
children may interpret their acceptance of the vaccine as
approval of sexual activity. Parents are concerned that
their children may see HPV immunization as blanket pro-
tection against the effects of sexual risk-taking. Parents
who reject the vaccine may believe that their children’s
‘safe’ or ‘moral’ behavior is adequate protection against
STI. In the absence of balanced public health information,
media reportage has stoked community concerns about
the effects of HPV vaccines on teen behavior [9,72-76]. In
the public health perspective, health is a public good
rather than a means for profit. The public funding, deliv-
ery and allocation of a vaccine are informed by the idea of
immunization as a public good. The public profile of the
HPV vaccine has been undermined by infomercials that
create the impression of a personalized ‘drug against risk,’
an object for commercial profit and consumer desire,
separate from public health considerations of community,
equity, and accessibility [65,77].
The high cost of the vaccine has compelled public
payers to ration its subsidization to unexposed adolescent
females with the expectation that high uptake will build
herd immunity. This has resulted in HPV, HPV-related
disease, and HPV vaccine being marked as ‘women-only,’
despite the fact that men also get and transmit the virus.
The prescription of ‘HPV immunization for girls’ to ensure
‘herd immunity’ suggests that HPV is an exclusively het-
erosexual concern. HPV also affects lesbian, gay, bisexual
and transgender (LGBT) people. HPV vaccine commer-
cials and public health messages focus on cervical cancer,
to the exclusion of throat, anal and penile cancer [78].
Despite the reported prevalence of oncogenic HPV type
16 in anal HPV infection, anal Pap smears are hindered by
silence, homophobia, lack of awareness, fear of stigma, and
unaddressed technological gaps [78]. Even in many high-
income countries, LGBT people may not seek sexual
health advice, or screening services due to fear of outing
and its consequences [79].
Focus on school-based immunization of preadolescent
girls removes attention from the risk faced by older
women from invasive disease due to persistent HPV infec-
tion [30]. In Canada and the US, women above 26 years of
age are not vaccine eligible [2,3]. Women in lower socio-
economic brackets would not be able to pay for the vac-
cine at its current cost. Funding for cervical screening pro-
grams for older, socioeconomically vulnerable women
should be strengthened. Exclusive strategic focus on HPV
immunization for younger women should not weaken
attention to the health needs of older women.
It will take at least 20 years of targeted immunization
of adolescent cohorts before there is a measurable
reduction in cervical cancer incidence [14]. In the short
term, HPV immunization may affect screening for
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may need re-training to accommodate new sensitivity
and specificity from higher rates of negative slides per
number viewed. HPV tests, if available at lower prices,
may prevent harms from reduced cytologic accuracy.
The creation and integration of immunization and can-
cer registries would facilitate monitoring of disease and
vaccine effectiveness, identification of vulnerable popula-
tions (mapping vaccine uptake and high-risk behaviour),
and the possible revision of screening guidelines [82-84].
Even in well-resourced settings, however, privacy laws
and issues related with transferring records from paper
to electronic formats may hamper surveillance [85].
These problems are exacerbated in developing countries
without the infrastructure or capacity for adequate
population health monitoring and databases.
Comparing Hepatitis B and human papillomavirus
immunization
The clinical efficacy of both HBV and HPV vaccines is in
their ability to block the acquisition of viruses that are
transmitted through non-casual intimate physical contact
(with HBV additionally blood-borne) [28,68,86]. Real-
world effectiveness, however, is in the prevention of
acute and chronic conditions and cancers induced by
persistent viral infection, e.g., fulminating hepatic necro-
sis, chronic infection with liver failure and primary hepa-
tocellular carcinoma from HBV and papillomatosis and
oropharyngeal and anogenital carcinomas from HPV
[27-31,68,86]. The clinical effectiveness of a vaccine
dovetails with cost-effectiveness when it is delivered to
populations with the greatest burden of disease. In this
area, HBV immunization has fared better than HPV
immunization and illustrates the important role of multi-
lateral partnerships in making new vaccines available to
vulnerable populations in developing countries.
At the time of introduction, both vaccines have raised
concerns about cost, cost-effectiveness, public acceptabil-
ity, and priority for public health [86,87]. A combination
of factors made the initially expensive HBV vaccine
(around US$ 100 during the early 1980s-1990s) available
for use in childhood immunization programs in develop-
ing countries [86]. These factors included technology
transfer for manufacturing a cheaper biogeneric at US$
1.00 per dose, feasibility demonstration projects of the
International Task Force on Hepatitis B Immunization,
and the intervention of GAVI to make the vaccine avail-
able in eligible countries [86]. In 1994, the World Health
Organization (WHO) incorporated HBV vaccine into the
Expanded Program on Immunization (EPI).
GAVI may be able to subsidize HPV vaccines for deliv-
ery in the poorest countries, provided vaccine manufac-
turers sell the vaccine to GAVI at lower prices [88]. This
process involves several stages: first, the vaccine price
reduction for country purchase; second, GAVI Board
approval for vaccine funding, conditional on availability
of funds; and finally, decision-making by GAVI-eligible
countries on the inclusion of HPV vaccine in national
immunization programmes [88]. Without cost reduction,
HPV vaccine cannot be offered for 9-13 year-olds
through the WHO EPI program, which provides the
infrastructure and public trust to have some success [35].
Such programs are not available in many emerging
economies. Thus, although some individuals may be able
to purchase the vaccine, it remains out of reach to most
vulnerable women.
In the US, HBV vaccine mandates have been passed,
delivering an otherwise expensive vaccine to children prior
to their school entry. A comparison of the differing his-
tories of HBV and HPV vaccines in the US illustrates the
importance of institutional credibility, dialogue, and regu-
latory decisions related to licensing and implementation.
It took seven years for the HPV vaccine to go from FDA
approval in 1986, to the US Advisory Committee on
Immunisation Practices (ACIP) recommendations in 1991,
to mandated requirement for day care attendance, in
1993. This time, along with its cost-reducing inclusion in
the Vaccines for Children (VFC) program in 1994, pro-
vided the opportunity for the public to become aware of
HBV immunization and accept its mandate [89]. In con-
trast, the rush to mandate Gardasil in 2007 (Texas, subse-
quently overturned) after its 2006 licensing, accompanied
by an aggressive marketing campaign, attracted criticism
and controversy. The intrusion of pharmaceutical interests
into health policy was suggested [64,89-91]. This speed
contributed to suspicions rather than building public
awareness and acceptance of HPV immunization. After
much legislative debate in several US states, only Virginia
and the District of Columbia passed HPV mandates, with
extensive opt-out provisions [89,91].
Immunization against HPV, unlike that against HBV,
specifically and conspicuously targets female adolescents
[92]. Socially entrenched anxieties about female sexuality
are activated to a greater extent and influence the public
reception of HPV immunization [62,63]. These views
should be debated through a free and, if necessary, even
protracted, exchange of views and information. Acceler-
ated vaccine rollouts, regardless of intention, limit the pos-
sibility of debate and exchange of views.
From laboratories to people: Complex itineraries for HPV
vaccines
The successful development and market authorization of
vaccines do not in themselves realize the public health
purposes of immunization. A vaccine, no matter how
innovative and efficacious, serves public health only if it
is a safe, affordable, accessible and cost-effective inter-
vention. There are multiple barriers to making HPV
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developing, economies. In general, the delivery of
vaccines in developing countries faces a wide range of
socio-technical challenges that include lack of institu-
tional capacity for monitoring of pre-market vaccine
quality and safety and post-market surveillance for
adverse events following immunization (AEFI), cold
chain difficulties in vaccine delivery to populations in
remote rural areas, risk of infection during needle-
administration, and fear of needles [23]. With HPV
vaccines, there are other, specific challenges.
As discussed, the availability of HPV vaccines in devel-
oping countries is particularly hampered by high vaccine
costs, bottlenecks of technology transfer for developing
cheaper subsequent entry vaccines, low acceptability of
vaccines against STI for pre-adolescents, and the pro-
blems of integrating HPV vaccines into the formularies
of country EPIs [19-21]. These challenges are summar-
ized in Table 1. For policy makers in developing coun-
tries, the prevention of a disease that manifests years in
the future has less political urgency than the immediate
prevention of conspicuous diseases such as poliomyelitis,
tuberculosis, or HIV/AIDS. For an individual, hunger
and inadequate shelter trump concerns about a silent,
slow-developing cancer. The risk-benefit profiles that
drive health decision-making in a well-off economy do
not apply in contexts where political violence, forced
migration, epidemics (e.g., cholera, meningitis), drought,
floods, crop failure, and starvation threaten daily survi-
val. Despite promising clinical data, questions persist
about immunogenic duration and the need for boosters
on HPV vaccine effectiveness [93]. These issues have
significant cost-effectiveness implications for poorer
individuals, communities, and countries. The currently
available vaccines target 16 and 18, two of the 15 most
prevalent high-risk HPV types. Among the types not
targeted, HPV types 45 and 31 are prevalent, respec-
tively, in sub-Saharan Africa and Central/South Amer-
ica. The development of effective multi-antigen HPV
vaccines, however, may be challenged by cross-reactivity
between included antigens [27]. The early age of immu-
nization (9 years for Gardasil
®) also remains conten-
tious. Despite clinical data that supports targeting
unexposed recipients, parental beliefs about the appro-
priateness of pre-adolescent immunization limit the
uptake of HPV vaccines among pre-teens. Vaccine deci-
sions are made not only by designated policy-makers
but also by the public, whose knowledge, attitudes and
beliefs (KAB) are key factors in vaccine acceptance.
Consistently, across a wide range of countries and ethni-
cities, KAB studies report socio-cultural barriers to HPV
vaccines. These include lack of awareness about HPV
effects and protections, parental and physician unwill-
ingness to vaccinate or to discuss sex and STI with
preadolescent females, concerns about vaccine costs and
uncertain duration of effectiveness, fear of unethical
motives and practices in vaccine trials, fear of needle
pain, adverse effects (e.g., infertility and physical disfig-
urement), socially unacceptable vaccine ingredients (e.g.,
alcohol, a concern for Muslims), stigma and sexual dis-
inhibition [94-110].
Uncertainties and fears associated with unknown sub-
stances in the vaccine can discourage some. Rumors of
adverse (or rumoured deliberate) effects, such as sterili-
zation, led to the failure of polio vaccine initiatives in
northern Nigeria [111]. A 3-dose HPV vaccine schedule
poses compliance burdens. Information written in a vac-
cine booklet is not accessible to women without literacy.
Further, keeping a vaccine booklet intact and legible
may be a problem for those living in huts with termites
and leaking roofs [112].
Even if inexpensive HPV vaccines could be developed,
manufactured, subsidized and supplied with quality
assurance, parents may not always accept immunization
of their pre-adolescent children for an STI [71]. Chal-
lenges of knowledge translation that have hampered
efforts to promote cervical screening may carry over to
HPV immunization. For instance, in a Hong Kong study
of attitudes to HPV immunization, Chinese participants
thought that HPV caused disease of the nipple, because
the Chinese characters used for HPV translated as
‘breast’ or ‘nipple’ [95]. Misunderstandings such as these
can hamper both the perceived need for health protec-
tions and efforts to obtain them. Physicians, who play a
key role in knowledge exchange and uptake of health
protections, report confusion about HPV, HBV, Herpes
Simplex virus (HSV), and Human Immunodeficiency
Virus (HIV) [113,114]. KAB studies demonstrate the
absence of a reliable body of publicly accessible informa-
tion on cervical cancer and its link to HPV. Individuals
may not perceive themselves at risk for HPV-related dis-
ease, especially when they are not having sex, or are in
monogamous marital relationships [94,95,99,106,108].
The lack of awareness of HPV transmission and health
risks may be exacerbated by the length of time from
infection to disease. In strongly male-dominated socie-
ties, values of shame and honour prevent women’sm a t -
ters, including female anatomy and STIs, from being
openly discussed and define ‘modest womanhood’ [115].
These are powerful social barriers to effective dialogue
about HPV and cancer. Indian physicians, for example,
are reluctant to discuss STIs and prophylaxis with
female patients or their families and see HPV immuni-
zation as an unnecessary addition to already heavy case-
loads [110].
The integration of screening and immunization into
public health education is critical to efforts to control
cervical cancer [116]. The evidence generated by KAB
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programs about the risks of HPV and the need to take
action against it. Text-heavy or hard-to-access web-
based information will not reach the illiterate or those
without computers [113]. Simple messages through low-
cost outreach strategies (e.g., street theater, door-to-
door visits by community workers, discussions at mar-
kets and bus stops) could more effectively engage the
community [113,117]. Messaging must convey that both
men and women are sufferers and carriers of HPV and
that HPV is neither an exclusively female problem nor a
matter of shame for women. Information about HPV
and cervical cancer need to target males, who in tradi-
tional societies are often key decision makers, even in
deciding women’s visits to clinics [95,103,107,108,112].
HPV immunization: Comparing implementation scenarios
Internationally, the implementation of HPV immuniza-
tion has had a variety of outcomes, associated with a
constellation of factors affecting health practicalities,
policies and priorities.
Australia, Canada and the UK have publicly funded pro-
grams that provide HPV immunization for peri-adolescent
girls through school based and catch-up programs
[80,118,119]. In the EU countries offering subsidized HPV
immunization, funding modalities and target populations
are heterogeneous [120,121]. Vaccine delivery in the EU is
school-based, or on-demand from general practitioners or
public health clinics, with or without a letter of invitation
[120,121]. While the vaccine is offered through public
health systems in Denmark, France, Germany, Italy, Spain,
the Netherlands, and the UK, the Austrian government
decided against including the vaccine in publicly funded
immunization programs. They reasoned that it would not
be as cost-effective as Pap testing; even with a high and
sustained uptake among both boys and girls, there would
be no appreciable reductions in cervical cancer for many
decades [121]. In the UK, reduced acceptability of the
Table 1 From Laboratories to People: Barriers in HPV vaccine implementation
INNOVATION PROCUREMENT AND DELIVERY POLICY FORMULATION SOCIAL CHALLENGES
(Knowledge, attitudes, beliefs)
Patent monopolies [19]. Inadequate regulatory mechanisms, resources
and infrastructure, i.e., for reporting of adverse
events and post-market surveillance [23,129].
High vaccine costs [18]. Parents and adolescents
[94-97,99-109]
Scarcity of instruments and
models for technology transfer
of inexpensive biogenerics
[19,21].
Cold chain issues, preventing quality- assured
and controlled transportation and storage of
vaccines [23,129].
Competing health priorities
(e.g., HIV/AIDS, malaria) [105].
Perceived low HPV/STI
susceptibility.
Gaps in multilateral funding for
vaccine procurement [20].
Controversies over HPV
vaccine mandates
[64-66,86,89-91].
Unwillingness to discuss sex and
STI.
Inadequate knowledge
exchange about STI risks and
need for prevention
[110,113,114].
Perceived inappropriateness for
pre-adolescents.
Stigma, loss of privacy.
Concerns about adolescent
promiscuity and beliefs in moral
education and marital
monogamy.
Suspicion of commercial motives
and unethical vaccine trials.
Worry about vaccine ingredients
and adverse effects.
Needle fears.
Gaps in availability and access.
Competing life priorities and
pressures.
Vaccine costs and duration of
effectiveness.
Healthcare providers [98,110]
Unwillingness to endorse
vaccine, discuss sex and STI, or
to stock vaccine
Lack of personnel and facilities
for vaccination and heavy case
loads in clinics.
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debunked link between autism and Measles-Mumps-
Rubella (MMR) vaccine [121]. Few Eastern European
countries have adopted HPV into their national immuni-
zation programs. These countries also lack organized
screening programs, possibly indicating their lack of
resources [16].
In the US, HPV immunization is available outside the
school system. Uninsured adolescents in the age-eligible
cohort can obtain the vaccine free of cost through
the VFC program [89]. For others, HPV immunization
depends either on individual ability to buy the vaccine or
on the extent of insurance coverage. There are no estab-
lished guidelines or standards for adolescents’ visits to
doctors. Adolescents are confronted by waning immunity
as well as poorer compliance with clinic visits required by
multi-dose schedules [117,122,123]. In Canada, HPV
immunization is delivered as part of the standard school
vaccine formulary through public-health mechanisms to
girls in Grades 7 and 8 [124]. Immunization requires
informed and voluntary parental consent [125]. According
to Canada’s National Advisory Committee on Immuniza-
tion (NACI), a rationale for targeting Grade 7 girls for
HPV immunization is that school-dropouts and sexual
activity are still relatively limited in that cohort [2]. In
Canada, HPV immunization is delivered alongside
accepted and normalized vaccines (e.g., HBV) through
established public-health systems [92,124,125]. This inte-
gration of HPV vaccine into existing delivery systems may
have softened the controversy and operational problems of
a federally-directed vaccine roll-out, whose speed pre-
cluded prior consultation and knowledge-sharing with
Canadian stakeholders at the provincial and territorial
levels [77,126,127].
In developing countries, HPV vaccines are not offered
as part of national immunization schedules. Immuniza-
tion costs are not covered and vaccine uptake may be
determined by the market (and marketing). Although
school-based delivery platforms have a good performance
record and are relatively equitable, they may have less
success in many developing countries. Even where
schools are available, young girls are often unable to
attend due to obligations both in and outside the home.
These programs also bypass street-dwelling youth in
developing and advanced economies [128]. Catch-up
immunization programs are only marginally successful.
Mandatory HPV immunization, although effective, would
strain the health budgets of developing countries.
Conclusion
Although HPV vaccines represent a promising biological
innovation, they will yield the greatest public health
benefits only when introduced at affordable prices into a
context of robust healthcare infrastructure. Determining
which vaccines to include in a public health program
requires capacity-intensive infrastructure for the regula-
tion, production, and post-market surveillance of vac-
cines [129]. In the event that HPV vaccines become
available at lower prices in developing countries, gaps in
capacity in these countries lends difficulties to effective
decision-making, delivery, and surveillance.
HPV vaccine remains unavailable to poor and vul-
nerable women. Those most able to access HPV
immunization may be also those more able to access
cervical screening [80]. The result is a widening of
health disparities, in both developing and developed
countries. Socioeconomic inequalities persist in the
inability of vulnerable women to access health services,
even in countries with a national health service. As
competition reduces costs and HPV vaccines become
accessible in poorer regions, it will remain important
for individuals, communities and health care providers
to engage in dialogue about HPV transmission, risks,
disease, and prevention through cervical screening as
well as immunization.
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